Modeling the bacterial dynamics in the gut microbiota following an antibiotic-induced perturbation

CPT Pharmacometrics Syst Pharmacol. 2022 Jul;11(7):906-918. doi: 10.1002/psp4.12806. Epub 2022 May 18.

Abstract

Recent studies have highlighted the importance of ecological interactions in dysbiosis of gut microbiota, but few focused on their role in antibiotic-induced perturbations. We used the data from the CEREMI trial in which 22 healthy volunteers received a 3-day course of ceftriaxone or cefotaxime antibiotics. Fecal samples were analyzed by 16S rRNA gene profiling, and the total bacterial counts were determined in each sample by flux cytometry. As the gut exposure to antibiotics could not be experimentally measured despite a marked impact on the gut microbiota, it was reconstructed using the counts of susceptible Escherichia coli. The dynamics of absolute counts of bacterial families were analyzed using a generalized Lotka-Volterra equations and nonlinear mixed effect modeling. Bacterial interactions were studied using a stepwise approach. Two negative and three positive interactions were identified. Introducing bacterial interactions in the modeling approach better fitted the data, and provided different estimates of antibiotic effects on each bacterial family than a simple model without interaction. The time to return to 95% of the baseline counts was significantly longer in ceftriaxone-treated individuals than in cefotaxime-treated subjects for two bacterial families: Akkermansiaceae (median [range]: 11.3 days [0; 180.0] vs. 4.2 days [0; 25.6], p = 0.027) and Tannerellaceae (13.7 days [6.1; 180.0] vs. 6.2 days [5.4; 17.3], p = 0.003). Taking bacterial interaction as well as individual antibiotic exposure profile into account improves the analysis of antibiotic-induced dysbiosis.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Anti-Bacterial Agents / adverse effects
  • Bacteria / genetics
  • Cefotaxime / adverse effects
  • Ceftriaxone / adverse effects
  • Dysbiosis / chemically induced
  • Dysbiosis / drug therapy
  • Gastrointestinal Microbiome* / genetics
  • Humans
  • RNA, Ribosomal, 16S / genetics

Substances

  • Anti-Bacterial Agents
  • RNA, Ribosomal, 16S
  • Ceftriaxone
  • Cefotaxime